Progenity celebrates the Society for Maternal-Fetal Medicine's focus on preeclampsia diagnostics, highlighting the challenges in this area. The Preecludia™ test, set to launch in the second half of 2021, will be the first U.S. test specifically designed to rule out preeclampsia, based on biomarkers from multiple pathophysiological pathways. Preeclampsia, a significant cause of maternal mortality, affects over 700,000 women annually. The company aims to address this unmet need through its innovative biomarker assay.
Progenity, Inc. (Nasdaq: PROG), a biotechnology firm known for its molecular testing products, announced that CEO Dr. Harry Stylli will participate in two virtual investor conferences. The events are a fireside chat at the BTIG Virtual MedTech Conference on February 17, 2021, at 2 p.m. ET, and another at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 3 p.m. ET. Live webcasts will be available on Progenity's investor website, with archived replays to follow each event.
Progenity aims to enhance healthcare precision through innovative testing and therapies.
PROG Holdings, Inc. (NYSE-PRG) announced a conference call on February 25, 2021, at 8:30 a.m. Eastern Time to discuss its Fourth Quarter 2020 financial results, which will be released before market opening that day. The call can be accessed by dialing 877-270-2148 or via the investor relations website investor.progleasing.com. PROG Holdings provides lease-purchase solutions for consumers through over 20,000 locations across 46 states, offering products such as furniture and electronics.
Progenity celebrates its 10-year anniversary, marking a milestone of two million diagnostic tests completed at its Ann Arbor laboratory. Established in 2011, the biotechnology firm has developed a range of molecular testing products, including the Preparent® Carrier Test and Innatal® Prenatal Screen. Exciting future innovations are planned, including the Preecludia™ test for preeclampsia and a novel ingestible technology for gastrointestinal disorders. CEO Harry Stylli emphasizes the company's commitment to advancing diagnostic capabilities and addressing unmet medical needs.
Progenity, Inc. (Nasdaq: PROG) announced its financial guidance for 2021, projecting total revenue growth of up to 30%, with expected earnings between $130 million and $145 million. Core molecular testing revenue is forecasted at $115 million to $125 million, while SARS CoV-2 testing is estimated to generate $15 million to $20 million. The company expects substantial growth in core testing volume, aiming for 290,000 to 310,000 tests. Progenity also emphasizes ongoing cost management and R&D disciplines amidst planned advancements in its product lines.
Progenity, Inc. (Nasdaq: PROG) will participate in the 2021 ICR Conference on January 14, 2021, at 4 p.m. ET. CEO Harry Stylli will present a company overview during the event. A live audio webcast will be accessible on Progenity's website, with an archived replay available post-event.
Progenity focuses on developing and commercializing molecular testing products and innovations in precision medicine, aiming to enhance healthcare through accurate diagnostics and targeted treatments.
Progenity, Inc. (Nasdaq: PROG) has expanded its COVID-19 RT-PCR testing services nationwide to meet rising demand. This testing is conducted through Avero Diagnostics, leveraging existing molecular testing expertise. The RT-PCR testing utilizes the Thermo Fisher Applied Biosystems TaqPath COVID-19 Combo Kit and has received Emergency Use Authorization from the FDA. Currently, turnaround time for results is 24-48 hours, with 97% of tests reported within 24 hours. Progenity’s goal is to aid healthcare providers amidst the pandemic while also continuing its focus on innovative molecular testing products.
Progenity, Inc. (NASDAQ: PROG) has successfully closed an offering of $85.5 million in 7.25% convertible senior notes due 2025. This includes $10.5 million from an exercise of an option by initial purchasers. Athyrium Capital Management affiliates acquired $103.5 million in these notes, with $25 million in cash and $78.5 million exchanged from a credit agreement. Additionally, Progenity closed a public offering of 7,645,259 shares at $3.27 each, generating gross proceeds of $110.5 million. Proceeds will support operations and R&D in molecular testing and precision medicine.
Progenity, a biotechnology firm, has successfully closed an underwritten public offering of 7,645,259 shares at $3.27 each, generating approximately $25 million. The offering was conducted under a registration statement effective December 2, 2020. Additionally, Progenity closed a private offering of $85.5 million in convertible senior notes due in 2025. The total gross proceeds from both offerings amount to $110.5 million, aimed at enhancing operations, funding molecular testing R&D, and supporting precision medicine initiatives.
Progenity, Inc. (NASDAQ: PROG) announced the pricing of $75 million in 7.25% convertible senior notes due 2025, set to settle on December 7, 2020. The notes will accrue interest semi-annually and are convertible into common stock at a rate of 278.0094 shares per $1,000 principal amount. Progenity anticipates net proceeds of approximately $70.8 million, which will be allocated to operations, R&D for molecular testing, and working capital. Additionally, Progenity priced an underwritten public offering of 7,645,259 shares of common stock at $3.27 per share.